SG Americas Securities LLC Acquires New Holdings in Savara Inc (NASDAQ:SVRA)

SG Americas Securities LLC acquired a new position in shares of Savara Inc (NASDAQ:SVRA) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 45,259 shares of the company’s stock, valued at approximately $192,000.

Other hedge funds have also recently made changes to their positions in the company. Janus Henderson Group PLC grew its holdings in Savara by 41.1% in the first quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock worth $12,754,000 after purchasing an additional 746,407 shares during the last quarter. Wellington Management Group LLP purchased a new stake in Savara in the fourth quarter valued at about $9,683,000. Vanguard Group Inc. boosted its holdings in Savara by 2.5% in the first quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock worth $30,197,000 after acquiring an additional 148,673 shares in the last quarter. Swiss National Bank purchased a new stake in shares of Savara during the first quarter worth about $732,000. Finally, Frazier Life Sciences Management L.P. increased its holdings in shares of Savara by 103.9% during the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock valued at $32,874,000 after acquiring an additional 4,157,385 shares in the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Stock Performance

SVRA opened at $3.41 on Thursday. The stock has a market cap of $471.22 million, a P/E ratio of -9.22 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a current ratio of 11.31 and a quick ratio of 11.31. The firm has a fifty day moving average price of $4.14 and a 200 day moving average price of $4.33. Savara Inc has a 1 year low of $3.12 and a 1 year high of $5.70.

Savara (NASDAQ:SVRA) last posted its earnings results on Monday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). Equities research analysts anticipate that Savara Inc will post -0.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

SVRA has been the subject of a number of recent analyst reports. Guggenheim lifted their target price on shares of Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. JMP Securities reissued a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research report on Tuesday, October 1st. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Savara in a research note on Tuesday, October 8th. Finally, Oppenheimer boosted their price target on Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a research note on Wednesday, June 26th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Savara currently has a consensus rating of “Buy” and a consensus target price of $11.17.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.